News Column

Eleven Biotherapeutics to Participate in Upcoming Investor Conferences in September

August 28, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, Ph.D., President and Chief Executive Officer, will participate in the following upcoming investor conferences in September:

  • Citi 9th Annual Biotech Conferencein Bostonon Thursday, September 4, 2014. Management will participate in a panel discussion entitled “Emerging Ophthalmology Therapies: Getting 20/20 on the Drug Landscape” at 12:00 p.m. E.T.
  • NewsMakers in the Biotech Industry Conferencein New York on Friday, September 26, 2014. Management will present a corporate overview at 11:00 a.m. ET.

    A live webcast of the NewsMakers in the Biotech Industry Conference can be accessed from the Investors & Media section of Eleven’s website at An archived replay of the webcast will be available on the Company’s website for 7 days after the conference.

    About Eleven Biotherapeutics

    Eleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, the Company’s understanding of the structural biology of cytokines and the Company’s ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects.

    Eleven Biotherapeutics

    Leah Monteiro, 617-714-0619

    Source: Eleven Biotherapeutics

  • For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

    Source: Business Wire

    Story Tools
 Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters